325 related articles for article (PubMed ID: 17317821)
21. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
Liu H; Li P; Zhai Y; Qu CF; Zhang LJ; Tan YF; Li N; Ding HG
World J Gastroenterol; 2010 Sep; 16(35):4410-5. PubMed ID: 20845507
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival.
Li T; Yin J; Yuan L; Wang S; Yang L; Du X; Lu J
Oncol Rep; 2014 Apr; 31(4):1699-706. PubMed ID: 24549282
[TBL] [Abstract][Full Text] [Related]
23. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
[TBL] [Abstract][Full Text] [Related]
24. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma.
Vongsuvanh R; van der Poorten D; Iseli T; Strasser SI; McCaughan GW; George J
PLoS One; 2016; 11(5):e0155800. PubMed ID: 27219517
[TBL] [Abstract][Full Text] [Related]
25. Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers.
Liu X; Wang SK; Zhang K; Zhang H; Pan Q; Liu Z; Pan H; Xue L; Yen Y; Chu PG
Carcinogenesis; 2015 Feb; 36(2):232-42. PubMed ID: 25542894
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
27. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.
Sun B; Huang Z; Wang B; Yu Y; Lin S; Luo L; Wang Y; Huang Z
Med Sci Monit; 2017 Feb; 23():850-855. PubMed ID: 28207681
[TBL] [Abstract][Full Text] [Related]
28. Expression of β-catenin protein in hepatocellular carcinoma and its relationship with alpha-fetoprotein.
Ren YJ; Huang T; Yu HL; Zhang L; He QJ; Xiong ZF; Peng H
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):846-851. PubMed ID: 27924522
[TBL] [Abstract][Full Text] [Related]
29. [Differential analysis of gene expression profiles in hepatocellular carcinoma patients with high and low levels of alpha-fetoprotein].
Wang XJ; Shen RF; Wang X; Wang YR; Xiao T
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):396-402. PubMed ID: 32482029
[No Abstract] [Full Text] [Related]
30. Immunohistochemical demonstration of alpha-fetoprotein in small hepatocellular carcinoma.
Sato K; Tanaka M; Kusaba T; Fukuda H; Tanikawa K
Oncol Rep; 1998; 5(2):355-8. PubMed ID: 9468556
[TBL] [Abstract][Full Text] [Related]
31. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma.
Shimizu D; Kanda M; Nomoto S; Oya H; Takami H; Hibino S; Suenaga M; Inokawa Y; Hishida M; Takano N; Nishikawa Y; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Oncol Rep; 2014 Mar; 31(3):1305-13. PubMed ID: 24366000
[TBL] [Abstract][Full Text] [Related]
32. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma.
Zhang C; Li Z; Cheng Y; Jia F; Li R; Wu M; Li K; Wei L
Clin Cancer Res; 2007 Feb; 13(3):944-52. PubMed ID: 17289889
[TBL] [Abstract][Full Text] [Related]
33. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma.
Beneduce L; Castaldi F; Marino M; Quarta S; Ruvoletto M; Benvegnù L; Calabrese F; Gatta A; Pontisso P; Fassina G
Cancer; 2005 Jun; 103(12):2558-65. PubMed ID: 15887222
[TBL] [Abstract][Full Text] [Related]
34. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients.
Okamoto M; Utsunomiya T; Wakiyama S; Hashimoto M; Fukuzawa K; Ezaki T; Hanai T; Inoue H; Mori M
Ann Surg Oncol; 2006 Jul; 13(7):947-54. PubMed ID: 16788756
[TBL] [Abstract][Full Text] [Related]
35. Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search.
Moribe T; Iizuka N; Miura T; Stark M; Tamatsukuri S; Ishitsuka H; Hamamoto Y; Sakamoto K; Tamesa T; Oka M
Int J Oncol; 2008 Nov; 33(5):949-58. PubMed ID: 18949357
[TBL] [Abstract][Full Text] [Related]
36. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.
Wang Y; Yang H; Xu H; Lu X; Sang X; Zhong S; Huang J; Mao Y
J Gastroenterol Hepatol; 2014 Mar; 29(3):597-602. PubMed ID: 24236824
[TBL] [Abstract][Full Text] [Related]
37. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
Li J; Wei L
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
[TBL] [Abstract][Full Text] [Related]
38. [CK19 can be used to predict the early recurrence and prognosis of HBV-related hepatocellular carcinoma patients with low AFP serum concentration after R0 radical hepatectomy].
Wang ZS; Wu LQ; Yi X; Geng C; Li YJ; Yao RY; Hu WY; Han B
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):753-8. PubMed ID: 23291069
[TBL] [Abstract][Full Text] [Related]
39. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
[TBL] [Abstract][Full Text] [Related]
40. [Correlation of perioperative alpha-fetoprotein expression in peripheral blood to recurrence of hepatocellular carcinoma].
Shi M; Zhang Y; Zhong C; Lin XJ; Zhang CQ; Li JQ
Ai Zheng; 2008 Jan; 27(1):83-7. PubMed ID: 18184471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
